Adma biologics, inc. ADMA.US Overview
ADMA AI Analysis & Strategy
Analysis Conclusion
The stock, with its moderate value rating, suggests that existing positions can be retained. For initiating new positions, it's advisable to wait for a value score above 4 and a dividend score of 2 or higher.
ADMA Current Performance
-1.30%
Adma biologics, inc.
-1.19%
Avg of Sector
0.52%
S&P500
ADMA Key Information
ADMA Financial Forecast
Unit : USD
ADMA Earnings Table
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | 0.14 | 250% | -12.5% | 114.8M | 55.3% | -5.7% | 95.2% |
| 2024Q2 | 0.15 | 1,400% | 15.4% | 119.84M | 78.1% | 5.7% | 29.9% |
| 2024Q1 | 0.13 | 750% | 62.5% | 107.19M | 78.3% | 24% | 21.7% |
| 2023Q4 | 0.08 | 366.7% | 33.3% | 81.88M | 43.9% | 6% | -23.9% |
| 2023Q3 | 0.04 | 166.7% | -420% | 73.9M | 47.9% | 2.4% | 3.8% |
ADMA Profile
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.